Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Shu Yang IVIG in Primary Immunodeficiency
NCT06089122Phase 3Not yet recruiting
- Sponsor
- Azidus Laboratories Limited
- Start
- Apr 2024
- Primary completion
- Jan 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 3, open-label, single-arm trial of human immunoglobulin (pH 4) for intravenous injection in primary immunodeficiency disease (PID), sponsored by Azidus Laboratories Limited. Primary endpoint: Average of acute serious bacterial infections at 1 year. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
human immunoglobulin (pH 4) for intravenous injection
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT06089122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06089122.